Consultation outcome

Branded medicines: statutory scheme

• From: Department of Health and Social Care
• Published: 21 January 2020
• Last updated: 10 March 2020 — See all updates

This was published under the 2019 to 2022 Johnson Conservative government

This consultation has concluded

Read the full outcome

Proposed changes to the statutory scheme to control the costs of branded health service medicines: consultation response

PDF, 150 KB, 18 pages

Final impact assessment: statutory scheme to control costs of branded health service medicines

PDF, 581 KB, 39 pages

This file may not be suitable for users of assistive technology.

Request an accessible format.

If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email publications@dhsc.gov.uk. Please tell us what format you need. It will help us if you say what assistive technology you use.

Detail of outcome

The government has published its response to the consultation on proposed changes to the statutory scheme that controls the cost of branded health service medicines.

A revised payment percentage for 2020 will be set from 1 April 2020 and the payment percentage for 2021 has been adjusted. These are set out in the response document.

There have been changes to the impact assessment in response to consultation feedback.

The finalised regulations and explanatory memorandum have been published.

---

Original consultation

Summary

Proposed changes to the statutory scheme to control the costs of branded health service medicines.

This consultation ran from
11am on 21 January 2020 to 11:59pm on 17 February 2020

Consultation description

This consultation seeks views on proposed changes to the statutory scheme to control the costs of branded medicines.

The consultation focuses specifically on proposed amendments to the payment percentages that are currently set out in the legislation for the statutory scheme.

We propose adjusting the payment percentages for 2020 and 2021 to help ensure allowed growth in statutory scheme sales of branded medicines to the NHS is limited to the current rate of 1.1% per year.

Documents

Proposed changes to the statutory scheme to control the costs of branded health service medicines

HTML

Impact assessment: statutory scheme to control costs of branded health service medicines

PDF, 532 KB, 37 pages

This file may not be suitable for users of assistive technology.

Request an accessible format.

If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email publications@dhsc.gov.uk. Please tell us what format you need. It will help us if you say what assistive technology you use.

Published 21 January 2020
Last updated 10 March 2020 + show all updates

1. 10 March 2020

   Added the consultation response and final impact assessment.

2. 21 January 2020

   First published.